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Review
Pharmaceuticals and personal care products 
(PPCPs) include numerous chemical classes. 
Pharmaceuticals are used primarily to prevent 
or treat human and animal disease, whereas 
personal care products are used to improve 
the quality of daily life and include products 
such as moisturizers, lipsticks, shampoos, hair 
colors, deodorants, and toothpastes. Human-
use PPCPs are generally excreted and emitted 
into the sewerage system following use. The 
compounds may then be released into surface 
waters or enter terrestrial systems when sew-
age effluent is used for irrigation or where 
sewage sludge is applied as a fertilizer to agri-
cultural land (Kinney et al. 2006; Ternes 
et al. 2004). Veterinary pharmaceuticals are 
released to the environment either directly, 
from use in aqua culture and the treatment of 
pasture animals, or indirectly during the land 
application of manure and slurry from live-
stock facilities (Boxall et al. 2003a). PPCPs 
may also be released to the environment from 
manu facturing sites (Fick et al. 2009).
PPCPs have been detected in the natural 
environment across the world (e.g., Hirsch 
et. al. 1999; Kolpin et al. 2002; Ramirez et al. 
2009). Although reported concentrations 
are generally low, many PPCPs have been 
detected in a variety of hydrological, climatic, 
and land-use settings and some can persist in 
the environ ment for months to years (e.g., 
Monteiro and Boxall 2009). Pharmaceuticals, 
as well as several chemicals used in personal 
care products, are biologically active com-
pounds that are designed to interact with 
specific pathways and processes in target 
humans and animals. Concerns have there-
fore been raised about the potential effects of 
active PPCPs in the environ ment on human 
and environmental health; over the past 
15 years, a substantial amount of work has 
been done to determine the occurrence, fate, 
effects, and risks of PPCPs in the environ-
ment. Regulations have also been developed 
regarding the assessment of risks of environ-
mental exposure to PPCPs [e.g., Center for 
Drug Evaluation and Research (CDER) 
1998; Committee for Medicinal Products 
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Background: Over the past 10–15 years, a substantial amount of work has been done by the 
 scientific, regulatory, and business communities to elucidate the effects and risks of pharmaceuticals 
and personal care products (PPCPs) in the environment. 
oBjective: This review was undertaken to identify key outstanding issues regarding the effects of 
PPCPs on human and ecological health in order to ensure that future resources will be focused on 
the most important areas. 
data sources: To better understand and manage the risks of PPCPs in the environment, we used 
the “key question” approach to identify the principle issues that need to be addressed. Initially, 
questions were solicited from academic, government, and business communities around the world. 
A list of 101 questions was then discussed at an international expert workshop, and a top-20 list was 
developed. Following the workshop, workshop attendees ranked the 20 questions by importance.
data synthesis: The top 20 priority questions fell into seven categories: a) prioritization of substances 
for assessment, b) pathways of exposure, c) bioavailability and uptake, d) effects  characterization, e) risk 
and relative risk, f ) anti biotic resistance, and g) risk management.
conclusions: A large body of information is now available on PPCPs in the environment. This 
exercise prioritized the most critical questions to aid in development of future research programs on 
the topic.
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for Human Use (CHMP) 2006; Committee 
for Medicinal Products for Veterinary Use 
(CVMP) 2000, 2004; European Centre 
for Ecotoxicology and Toxicology of 
Chemicals (ECETOC) 2008; World Health 
Organization (WHO) 2011]. 
Attempts have been made to synthesize 
the wealth of knowledge gained to date and 
to identify the remaining major research gaps 
and gaps in regulation [e.g., Knowledge and 
Need Assessment of Pharmaceutical Products 
in Environmental Waters (KNAPPE) 2008]. 
However, these exercises have tended to focus 
on select regions of the world, as well as estab-
lished markets, and have not always engaged 
fully with major stakeholder groups.
One approach to identifying key issues 
in a topic area is to perform a “key ques-
tion exercise,” which is designed to promote 
engage ment of researchers and stake holders 
from a broad range of sectors (e.g., Fleishman 
et al. 2011; Rudd et al. 2011). The exercise 
begins with an initial solicitation of inter-
ested parties to develop a list of questions that 
individual members of the community feel 
are important regarding a particular topic. A 
workshop is then held to discuss and priori-
tize the questions raised and to develop a final 
list of questions (e.g., 20, 40, or 100). In this 
review we report the results of a key question 
exercise that was performed to identify and 
rank the top 20 questions related to the haz-
ards, exposure assessment, and environ mental 
and health risks of PPCPs in the natural 
environment. A description of the approach 
used, the submitted questions, and questions 
taken forward to the workshop is available 
in Supplemental Material, pp. 2–29 (http://
dx.doi.org/10.1289/ehp.1104477).
Top 20 Questions
The top 20 questions fell into seven categories: 
a) prioriti za tion of PPCPs, b) pathways of 
exposure, c) bioavailability and uptake, 
d) effects charac terization, e) risk and relative 
risk, f ) anti biotic resistance, and g) risk 
manage ment.
Prioritization of PPCPs
What approaches should be used to prioritize 
PPCPs for research on environmental and 
human health exposure and effects? More than 
4,000 pharma ceuti cals are currently in use, 
and many types of chemicals are used in per-
sonal care products; it would be impossible to 
experimentally assess the hazards and risks of 
all of these in a timely manner. Prioritization 
approaches can be used to focus monitoring, 
testing, and research resources and to iden-
tify those PPCPs that are likely to pose the 
greatest risk in a particular situation. Several 
prioriti za tion methods have been proposed 
for—and applied to—human pharmaceu-
ticals (e.g., Kostich et al. 2010; Kostich and 
Lazorchak 2007; Sanderson et al. 2004) and 
veterinary medicines (Boxall et al. 2003b; 
Capelton et al. 2006; Kools et al. 2008). Many 
of these approaches use either exposure and 
toxicological predictions or information on 
pharma ceutical potency, so they can be readily 
applied to large numbers of compounds. These 
approaches should be further developed for dif-
ferent situations covering different geo graphi cal 
regions, climates, demographics, and cultural 
backgrounds and should be designed in such 
a way that they account for the use practices, 
complex fate processes, and the specific modes 
of action associated with many PPCPs.
Pathways of Exposure
What are the environmental exposure path­
ways for organisms (including humans) to 
PPCPs in the environment, and are any of 
these overlooked in current risk assessment 
approaches? PPCPs can enter the environ-
ment by a number of pathways (Figure 1). 
Regulatory environ mental risk assessment 
approaches for PPCPs consider releases to 
surface waters from waste water treatment sys-
tems, aquaculture facilities, and runoff from 
fields, as well as releases to soils during bio-
solid and manure application [e.g., CHMP 
2006; CVMP 2008; Price et al. 2010). Other 
exposure pathways exist, including emissions 
from manu facturing sites (Fick et al. 2009), 
disposal of unused medicines to landfills, run-
off of veterinary medicines from hard surfaces 
in farmyards, irrigation with wastewater, off-
label emissions, and disposal of carcasses of 
treated animals. Management and use prac-
tices in different regions of the world can also 
vary, so an important exposure pathway in 
one geographical area may be a less important 
pathway in another region. For example, in 
several regions of the world, the connectivity 
of the population to wastewater treatment 
technologies is limited, so regulatory expo-
sure modeling based on European and North 
American systems will not always be relevant. 
An understanding of the release mechanisms 
and dominant exposure pathways for PPCPs 
in different regions is therefore needed.
Bioavailability and Uptake
How can the uptake of ionizable PPCPs into 
aquatic and terrestrial organisms and through 
food chains be predicted? A significant pro-
portion of PPCPs are ionizable substances. 
Although methods are available for estimating 
uptake of ionizable compounds into fish and 
invertebrates (e.g., Fu et al. 2009; Meredith-
Williams et al. 2012), our understanding of 
the factors and processes that influence uptake 
of PPCPs from different environ mental com-
partments into organisms is still less well 
developed than for non ionizable chemicals 
(Brooks et al. 2009). The uptake of ioniz-
able PPCPs is also very sensitive to changes in 
environ mental conditions such as pH and soil 
and sediment characteristics. Data on uptake 
through food chains is almost non existent. 
Future work should therefore focus on under-
standing the uptake routes for PPCPs from 
a range of matrices into single organisms 
and food webs covering different traits (e.g., 
size, life cycle characteristics, method of res-
piration). Based on these studies, improved 
models should be developed for estimating 
Figure 1. Major pathways of PPCP release into the environment. Reproduced from Boxall (2004) with per­
mission from EMBO Reports. 
Livestock
treatments
Treatment of
companion animals
Inappropriate disposal of
used containers and
unused medicine
Aquaculture
treatments
Manufacturing
process
Wastewater
treatments
Soil Receiving water
Storage of
manure and slurry
Manure/slurry spreading
PPCPs in the environment
Environmental Health Perspectives • volume 120 | number 9 | September 2012 1223
uptake of ionizable PPCPs into organisms 
and through food chains. 
What is the bioavailability of non­
extractable residues of PPCPs? Many PPCPs 
dissipate rapidly in animal manure, bio-
logical treatment processes, soils, and sedi-
ments. Data from degradation studies with 
radio labeled PPCPs indicate that, in many 
instances, the observed dissipa tion can be 
due to the formation of non extractable resi-
dues (NERs; e.g., Kreuzig and Höltge 2005). 
NERs are species of a chemical that cannot be 
extracted from a matrix (sediment, soil, etc.) 
by methods that do not significantly change 
the chemical nature of the residues. In gen-
eral, the chemical identities of these NERs are 
unknown. Concerns have been raised that, in 
the future, NERs may become bio available 
due to breakdown of manure and biosolid 
material added to soils, or due to changes 
in agricultural practices or the environ ment, 
such as changes in the pH or ionic strength 
of a system (Barraclough et al. 2005; Gevao 
et al. 2000). The challenge is to demon strate 
whether NERs for PPCPs are bio available or 
whether they are likely to become bio available. 
This is a challenge not only for PPCP risk 
assessment but also for other classes of chemi-
cals, including pesticides (e.g, Calderbank 
1989; ECETOC 2010).
Effects Characterization
How can pharmaceutical pre clinical and clini­
cal information be used to assess the potential 
for adverse environmental impacts of pharma­
ceuticals? A lot of information is available from 
mammalian studies and clinical trials on the 
behavior and effects of active pharmaceuti-
cal ingredients. The pharma ceuti cal indus-
try devotes signifi cant resources to collating 
new and emerging data as part of their post-
authorization pharmaco vigilance programs, 
and several epidemiological studies have been 
performed to explore the potential long-term 
health effects of pharmaceuticals on workers in 
the pharmaceutical industry (e.g., Heron and 
Pickering 2003). In contrast, comprehensive 
information on fate and effects in the environ-
ment is publicly available for only a small per-
centage of pharma ceuticals and, with a few 
exceptions (e.g., the U.K. Veterinary Medicines 
Directorate Suspected Adverse Reactions 
Reporting Scheme), pharmaco vigilance pro-
grams do not examine environ mental effects. 
By accessing the wealth of data from mam-
malian studies and clinical trials and by build-
ing upon the advanced methods for predicting 
long-term, low-level effects arising from occu-
pational exposure, it may be possible to estab-
lish whether low levels of a pharmaceutical in 
the environment constitute a threat to environ-
mental and human health (Ankley et al. 2007; 
Berninger and Brooks 2010; Huggett et al. 
2003; Seiler 2002).
What can be learned about the evolutionary 
conservation of PPCP targets across species and 
life stages in the context of potential adverse out­
comes and effects? Most pharmaceuticals, and 
a few personal care products, are designed to 
interact with a target (such as a specific recep-
tor, enzyme, or biological process) in humans 
and animals to deliver the desired therapeu-
tic effect. If these targets are present in organ-
isms in the natural environment, exposure to 
some PPCPs might be able to elicit effects in 
those organisms. Knowledge of the presence or 
absence of PPCP targets across a wide range of 
taxa could therefore be invaluable in identifying 
PPCPs that might affect the environment at 
low concentrations, and those organisms and 
life stages of organisms that are most likely to 
respond to exposure to a particular pharma-
ceutical (Ankley et al. 2007; ECETOC 2008; 
Gunnarsson et al. 2008; Huggett et al. 2003; 
Seiler 2002; Trudeau et al. 2005). Comparative 
bio chemistry, genomics, and other “omic” tech-
nologies offer potential tools for identifying 
PPCPs of potential concern, as well as the most 
sensitive and vulnerable species.
How can ecotoxicological responses, such 
as histological and molecular­level responses 
observed for PPCPs, be translated into tra­
ditional ecologically important end points, 
such as survival, growth, and reproduction of 
a species? This question is relevant to many 
other classes of environmental contami nants 
(Huggett et al. 1992). Responses such as histo-
logical changes, behavioral effects, bio chemical 
responses, and up- or down-regulation of genes 
have been observed in organisms exposed to 
PPCPs (Ankley et al. 2007; Brooks et al. 2009; 
Corcoran et al. 2010). These responses are gen-
erally not included in current risk assessment 
schemes but can occur at concentrations that 
are orders of magnitude lower than concentra-
tions at which effects are observed in regulatory 
tests, such as acute studies examining effects 
on fish and invertebrate mortality, or chronic 
studies looking at effects on reproduction and 
growth (Figure 2). The importance of these 
responses in terms of popu lation survival and 
eco system functioning is poorly understood. 
However, it is necessary to understand these 
relation ships in order to discover the broader 
implications of non standard observations on 
eco system health and to determine the benefits 
of incorporating data from non standard eco-
toxicological responses, such as histological and 
behavioral effects, into prospective and retro-
spective risk assessment frameworks. Unlike for 
many other chemical classes, our knowledge of 
the relationships between effects at the molecu-
lar level and effects at the whole-organism level 
in humans is very well developed. We may 
therefore be able to apply this knowledge to 
better understand relationships between molec-
ular, cellular, and whole-organism end points 
for organisms in the natural environment. 
How can ecotoxicity test methods that reflect 
the different modes of action of active PPCPs 
be developed and implemented in customized 
risk assessment strategies? Existing risk assess-
ment approaches for PPCPs in Europe and 
North America employ standard Organisation 
for Economic Co-operation and Development 
(OECD) test methods for examining effects 
on organisms (CDER 1998; CHMP 2006; 
CVMP 2000, 2004). Some authorities can ask 
for non standardized studies when a risk can-
not be ruled out by standard tests. Concerns 
have been raised over whether standard 
methods will identify ecologically important 
effects of specifically acting PPCPs (Brooks 
et al. 2009; ECETOC 2008). The effect of the 
non steroidal, anti-inflammatory compound 
diclofenac on vulture populations (Oaks et al. 
2004) is one example of an end point that 
would not have been predicted from stan-
dard studies. Further work is required to 
understand the effects of PPCPs with differ-
ent modes of action on aquatic and terrestrial 
organisms. Depending on the findings of this 
research, it may be appropriate to develop new 
guidance on the selection of eco toxicological 
test methods (species and end points) in the 
risk assessment process. However, it would 
be short sighted to restrict testing strategies 
only to methods that reflect specific modes of 
action because unexpected effects in organisms 
can occur, as illustrated by the high potency 
of fluoxetine, a selective serotonin reuptake 
inhibitor, in algae (Oakes et al. 2010).
How can effects from long­term exposure to 
low concentrations of PPCP mixtures on non­
target organisms be assessed? Aquatic and ter-
restrial systems will be exposed to a complex 
mixture of PPCPs and other contaminants. 
Figure 2. Relationship between results of acute and 
chronic studies (recommended for use in current 
regulatory assessment approaches for PPCPs in 
fish) and reported non standard end points in fish 
and invertebrates. Standard acute and chronic data 
(e.g., fish and invertebrate mortality, reproduction, 
and growth) were obtained from FASS.se (2011) and 
several litera ture sources (Caldwell et al. 2008; Kim 
et al. 2009; Yamamoto et al. 2007); non standard end 
point data were obtained from Corcoran et al. (2010).
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Many pharmaceuticals, if consumed together 
at therapeutic doses, can cause severe adverse 
inter actions in humans (e.g., Juurlink et al. 
2003). If aquatic organisms respond to these 
compounds in the same way as humans, 
effects on the environ ment could be greater 
than predicted based on effects data for the 
single compounds. Antimicrobial PPCPs 
may also increase persistence of other PPCPs, 
thus affecting the overall risk (Monteiro and 
Boxall 2009). Because many human-use 
PPCPs will be emitted continuously into the 
environ ment, organisms in the environ ment 
will be exposed throughout their lifetime. 
However, no regulatory program for prospec-
tive environ mental risk assessment of PPCPs 
(or other product classes) takes into account 
the long-term combined toxicity of mixtures 
of chemicals, so there is a need to develop 
new approaches for assessing the risks arising 
from long-term exposure to mixtures. The 
concept of mixture risk assessment is gath-
ering momentum, particularly in the pub-
lic health arena, and recent reports by the 
European Commission, the UK Committee 
on Toxicology, and the U.S. National 
Academy of Sciences have already started to 
consider this topic (e.g., Kortenkamp et al. 
2009). For human medicines, it may be pos-
sible to use observed contra indications in 
humans to provide an indication of whether 
a particular combination of pharmaceuti-
cals in the environment may be of concern. 
Mixture inter actions could also be simulated 
by pharmaco kinetic modeling, linking models 
at the inter action site (Krishnan et al. 2002), 
although this will require extensive quantita-
tive information on pharmaco kinetics and/or 
toxico kinetics. Although the use of in vitro 
assays for rele vant end points (e.g., carcino-
genic, mutagenic, and reproductive effects) 
to assess the effects of mixtures of pharma-
ceuti cals that typically occur in environ mental 
systems may also provide useful information 
for use in risk assessment, these will need to 
be extensively validated before use.
Can non animal testing methods be 
developed that will provide equivalent or better 
hazard data compared with current in vivo 
methods? For personal care products, there is 
regulatory pressure in some geographic regions 
to reduce the amount of animal testing used 
for human safety and environmental risk 
assessment in a 3Rs framework (reduce, refine, 
replace). It may be possible to reduce the 
amount of animal testing using nonanimal 
testing methods, such as in vitro approaches 
and in silico methods (e.g., quantitative 
structure–activity relationships, read-across and 
expert systems), by optimizing experimental 
designs, and by employing intelligent testing 
strategies (Hutchinson et al. 2003; OECD 
2010; Rufli and Springer 2011). Although 
these approaches are being promoted (e.g., 
National Academy of Sciences 2007) and 
used for industrial chemicals [e.g., as part 
of the REACH (Registration, Evaluation, 
Authorisation and Restriction of Chemical 
substances) regulations in Europe and 
elsewhere (Halder et al. 2010)], additional 
approaches are needed to replace animal test 
methods with methods able to evaluate specific 
and non specific modes of action. 
Risk and Relative Risks
How can regions where PPCPs pose the great­
est risk to environmental and human health, 
either now or in the future, be identified? Risks 
of PPCPs in the environment in different geo-
graphic regions vary because of differences in 
the presence/absence and type of manufac-
turing sites, level of PPCP use, population 
demographics, cultural practices, environ-
mental and climatic charac teristics, dilution 
potential of receiving environments, and 
infra structure related to wastewater and drink-
ing water treatment. Risks may change in the 
long term due to factors such as increased 
urbanization and effluent-dominated instream 
flows (Brooks et al. 2006), increased disease 
pressures, demo graphic change, population 
increases, technological developments (e.g., 
move from small molecules to biologics, 
development of nano medicines, improve-
ments in drug delivery), and climate change. 
By better understanding the drivers for PPCP 
exposure in different regions, it may be pos-
sible to identify those areas that are at great-
est risk, meaning that control options can be 
focused to areas/regions where they will be 
most effective. By understanding how risks 
will change in the longer term, it may be pos-
sible to anticipate and pre emptively mitigate 
against unacceptable changes in risks.
How important are PPCPs relative to 
other chemicals and non chemical stressors in 
terms of biological impacts in the natural envi­
ronment? PPCPs are released into the natural 
environment along with many other chemicals 
(e.g., nutrients, metals, industrial chemicals, 
pesticides, natural hormones). The natural 
environment is also exposed to non chemical 
stressors such as changes in water flow and 
temperature. The affect of PPCPs could be 
small compared with the many other chemical 
and non chemical stressors present in the natu-
ral environment. To make informed manage-
ment decisions, it is necessary to understand 
the relative impact of PPCPs compared with 
other pressures in a particular situation. 
Do PPCPs pose a risk to wildlife such as 
mammals, birds, reptiles, and amphibians? 
Most studies have focused on effects of PPCPs 
on fish and invertebrates, but our knowl-
edge of risks to other wildlife species, such 
as birds and small mammals, is less devel-
oped. Several case studies have highlighted 
the importance of under standing effects on 
birds and mammals. For example, the inap-
propriate use of diclofenac and associated cul-
tural practices regarding disposal of animal 
carcasses, combined with the high sensitivity 
of vultures to diclofenac, were responsible 
for the decline in populations of three vul-
ture species in Asia (Oaks et al. 2004), result-
ing in ecological, socio economic, cultural, 
and human health impacts (Markandya et al. 
2008). Indirect effects on top predators may 
also be important; for example, there is con-
cern that anti parasitic veterinary medicines 
may be indirectly affecting populations of 
insect-eating bats and birds by affecting the 
quantity of food available (McCracken 1993). 
More work is needed to better understand the 
exposure of birds, mammals, and amphibians 
to PPCPs, as well as the potential toxicologi-
cal effects of PPCPs on these species.
How can the environmental risks of 
metabo lites and environmental transformation 
products of PPCPs be assessed? Pharmaceuticals 
may be metabolized in the treated human or 
animal so that a mixture of parent compound 
and metabolites will be released into the envi-
ronment. Transformation of PPCPs will also 
occur in wastewater treatment processes, surface 
waters, sediments, manure, soils, and drinking 
water treatment processes (Escher and Fenner 
2011). Although metabolites and transforma-
tion products are usually less hazardous than 
the parent compound, data for pesticides indi-
cate that some can be more toxic (Sinclair and 
Boxall 2003). The environmental fate of these 
substances can also be different from the parent 
compound, meaning that environmental com-
partments that are not exposed to the parent 
may be exposed to a transformation product 
(Boxall et al. 2004). Concerns have also been 
raised over the potential human health effects 
of selected transformation products of PPCPs, 
such as the halogenated and nitrosamine prod-
ucts resulting from transformation in waste-
water and drinking water treatment processes 
(Sedlak and von Gunten 2011). We need to 
better understand the release and formation 
of transformation products of PPCPs in the 
environ ment and develop approaches for iden-
tifying transformation products that could pose 
a greater risk than the parent compound.
How can data on the occurrence of PPCPs 
in the environment and quality of eco systems 
exposed to PPCPs be used to determine whether 
current regulatory risk assessment schemes are 
effective? Environmental risk assessments for 
PPCPs have been required in Europe and 
North America for some time. The effectiveness 
of these prospective risk assessment approaches, 
in terms of predicting exposure and effects in 
the real world, is not always clear. By bring-
ing together data on the occurrence of PPCPs 
in different regions, as well as information on 
the status of biological communities and eco-
systems, it may be possible to establish whether 
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environ mental risk assessment schemes really 
work for PPCPs. This is a general issue rele-
vant to other classes of chemi cals that require 
an environ mental risk assessment. The appli-
cation of eco epidemiological approaches that 
link chemical pressures to effects on eco systems 
(e.g., De Zwaart et al. 2006) may help answer 
this question.
Antibiotic Resistance
Does environmental exposure to PPCP residues 
result in the selection of antimicrobial­resistant 
micro organisms, and is this important in terms 
of human health outcomes? The WHO (1998) 
identified the emergence of anti microbial 
resistance as one of the serious concerns of 
health policies in the future. One of the major 
concerns relating to the occurrence of anti-
biotic compounds in the environment is the 
potential for selection of resistant microbial 
species. Antibiotics in the environment may 
enhance the formation of single, cross-, and 
multiple-resistance in bacteria (e.g., Byrne-
Bailey et al. 2009; Gaze et al. 2011; Knapp 
et al. 2010; Kristiansson et al. 2011). However, 
the role of environ mental residues of anti-
biotics in the selection of anti biotic resistance 
is still unclear; even where information 
exists, it is only available for a few anti biotics 
(e.g., sulfonamides, fluoro quinolones). We 
need to better understand how anti biotic 
residues in the environ ment are involved in 
selecting for anti biotic resistance, as well as 
the potential for the acquired resistance to 
transfer to human and animal pathogens and 
thus affect human health. This assessment 
must be interpreted against the backdrop of 
anti biotic resistance (the resistome) naturally 
found in the environment or caused by 
inappropriate clinical use of anti biotics or 
other environmental contaminants.
How can the risks to human health that 
arise from anti biotic resistance selection 
by PPCPs in the natural environment be 
assessed? Current regulatory paradigms do 
not consider the potential for anti biotic resis-
tance selection in soils and surface waters. If 
the occurrence of anti biotics in the natural 
environ ment is demon strated to be an impor-
tant driver for resistance selection, it may be 
necessary to develop approaches for consider-
ing resistance selection in the natural environ-
ment as an end point in the safety assessment 
of new anti biotic substances. There is also 
a need to understand the extent to which 
feces from treated animals and humans act as 
an environ mental source of resistant micro-
organisms and associated genetic elements.
Risk Management
If a PPCP has an adverse environ mental 
risk profile, what can be done to manage 
and mitigate the risks? In the event that a 
PPCP poses an unacceptable risk to the 
environment, options exist for minimizing 
or removing emissions to the environment, 
including a) substitution of the compound 
with a more environ mentally benign com-
pound; b) develop ment of better drug 
delivery systems so that smaller doses are 
needed; c) improvement of packaging and 
package sizes to extend shelf life and reduce 
the amount of the product that expires and 
must be discarded unused; d) changes in pre-
scription and animal husbandry practices; 
and e) introduction of improved wastewater 
treatment options (e.g., Daughton 2003a, 
2003b; START 2008). However, the efficacy 
and practicality of many of these solutions 
is poorly understood. A systematic study is 
needed to determine the bene fits of different 
manage ment and mitiga tion options and any 
societal and environmental costs associated 
with a particular option in different regions of 
the world. This will allow informed decisions 
to be made on the best mitigation strategy.
What effluent treatment methods are effec­
tive in reducing the effects of PPCPs in the 
environment while not increasing the toxicity 
of whole effluents? During biological treatment, 
some PPCPs may be degraded or removed 
through sorption to sludge (Prasse et al. 2011; 
Ternes et al. 2004). Recalcitrant PPCPs may 
be removed using tertiary treatment methods 
such as ozonation, activated carbon adsorp-
tion, or nano filtration (Ternes et al. 2004). In 
some cases, the wastewater treatment process 
may increase the risk. For example, ozona-
tion may result in the formation of more toxic 
oxidation products. In other cases, the intro-
duction of a treatment option may move the 
exposure from one environ mental compart-
ment to another. For example, introduction 
of procedures to enhance sorption of PPCPs 
to activated sludge treatment will mean that 
while emissions to water bodies are reduced, 
exposure of the terrestrial environment will 
increase when the sludge is applied to soils 
as a fertilizer (McClellan and Halden 2010). 
Increased knowledge is required to determine 
the effectiveness and consequences of waste 
and drinking water treatment options on 
PPCP fate and effects.
How can the efficacy of risk management 
approaches be assessed? The introduction of risk 
management strategies can result in environ-
mental, economic, and societal costs. In these 
cases, management options should be proven 
to be effective at reducing environ mental 
impacts before they are widely introduced. 
Guidance is needed in evaluating environ-
mental monitoring approaches to determine 
the efficacy of particu lar manage ment options. 
These approaches should not only include 
monitoring of changes in the occurrence of a 
particular substance but also be able to moni-
tor changes (improvements) in the health of 
the eco system of interest. The costs (economic, 
social, and environmental) of a management 
option also need to be considered. Control 
options for anti microbial compounds (e.g., 
banning of anti biotic substances as growth 
promoters and/or prophylactic treatments in 
agriculture) may not be effective in controlling 
anti biotic resistance because once anti biotic 
resistance genes are present in the environment, 
they may not disappear. Other anthropogenic 
compounds will also facilitate the selection of 
micr organisms that are resistant to some classes 
of anti biotic (e.g., Gaze et al. 2011). 
Ranking of Questions and 
Next Steps
When questions were ranked in terms of 
importance, the question regarding the relative 
risks of PPCPs compared with other environ-
mental stressors was identified as the most 
important (Table 1). This reflects the signifi-
cance of the question for allocation of future 
research resources and the implementation of 
future policy development and risk manage-
ment options. If the answer to the question is 
that PPCPs are more important stressors than 
are other stressors in the environment, then 
many other questions identified in this exer-
cise will be rele vant and important. However, 
if PPCPs pose relatively minor risks com-
pared with other stressors in the environment, 
then expending large amounts of resources 
answering the other questions may not offer 
the best use of resources in terms of global 
environmental protection. Questions regard-
ing prioritization, improved characterization 
of effects, and anti biotic resistance were also 
ranked highly, whereas questions regarding 
risks of non extractable residues, treatment, 
and the use of non animal studies were ranked 
lower (Table 1). For each question, potential 
approaches that could be adopted to address 
the question were identified. We envisage that 
this information will be invaluable in formu-
lating future research programs involving the 
risks of PPCPs in the environment.
In the development of future research and 
policy initiatives, it is important to recognize 
that many of the questions are inter related 
and that knowledge gained from one ques-
tion may be needed to address other questions 
(Table 1). In some instances, it may be neces-
sary to address a lower-ranked question before 
a high-ranked question can be fully answered. 
For example, knowledge gained from answer-
ing questions around prioritization of PPCPs, 
the importance of the environment as a selec-
tion pressure for anti microbial resistance, 
identification of regions of greatest risk, and 
charac teriza tion of risks to wildlife may all 
need to be answered before the top-ranked 
question can be addressed. The level of chal-
lenge associated with answering a question also 
varies (Table 1). Questions regarding the risks 
of non extractable residues and prioritization 
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of PPCPs may be addressable with limited 
investment over relatively short time periods 
compared with other questions.
Many questions (e.g., the questions involv-
ing NERs, mixture interactions, and extrapola-
tion of results on molecular and cellu lar effects 
to ecologically rele vant end points) are not 
unique to PPCPs, so it may be appropriate 
to address these in broader research programs 
looking at other chemical classes. However, 
the detailed understanding that we have for 
the effects of many PPCPs on humans might 
make them good candidate model compounds 
for addressing some of these wider questions.
Wider Global Relevance of the 
Exercise
Although participants from different regions 
of the world were engaged in the exercise, 
most question submissions (92%) were from 
North America (46.6%), Europe (29.8%), and 
Australia/New Zealand (15.5%). The workshop 
Table 1. Ranking of key questions by workshop participants, along with potential approaches to address the questions, the interrelationships of the questions, and 
the degree of challenge required to address a question.
Rank Question
Most important 
question (%)a Potential approaches Related questions (by rank)
Level of 
challenge
1 How important are PPCPs relative 
to other chemicals and non chemical 
stressors in terms of biological 
impacts in the natural environment?
48.5 Comparative assessment of risks posed by PPCPs 
compared with other stressors; effects-driven analysis on 
ecologically important end points for effluent samples to 
identify the relative toxicity of the chemical components; 
eco epidemiological studies
Will inform whether resources 
should be expended on many 
other questions, particularly 
those around risk management 
(e.g., 14); data from 2, 3, 6, 
and 17 may help to answer the 
question
M–H
2 What approaches should be used 
to prioritize PPCPs for research on 
environmental and human health 
exposure and effects?
35.8 Review of existing prioritization approaches to 
identify advantages and limitations and geographical 
representativeness; development and application of new 
approaches for different scenarios and regions; review of 
existing prioritization approaches to determine whether 
similar PPCPs are highlighted against different prioritization 
metrics
5, 6, 9, and 19 may provide 
useful data
L–M
3 Does environmental exposure to PPCP 
residues result in the selection of anti-
microbial resistant micro organisms, 
and is this important in terms of 
human health outcomes?
34.3 Large-scale multidisciplinary studies to characterize the 
impacts of antibiotic residues on resistance in treatment 
systems, surface waters and soils; characterization of the 
degree of human exposure to resistance genes arising from 
the natural environment; comparison of antibiotics in the 
environment with other pressures, such as selection in the 
clinical setting and selection by other contaminants
Could help inform 11 H
4 How can ecotoxicological responses, 
such as histological and molecular-
level responses observed for 
PPCPs, be translated into traditional 
ecologically important end points such 
as survival, growth, and reproduction 
of a species?
32.7 Generation of data on effects of a range of PPCPs 
on organisms at different levels (biomarker through 
populations); use of organism and population models to 
attempt to explain the linkages
2 could inform which 
substances to focus on; 
information from 6 may help 
to answer this question
H
5 How can pharmaceutical preclinical 
and clinical information be 
used to assess the potential for 
adverse environmental impacts of 
pharmaceuticals?
32.4 Development of comparative datasets on preclinical, 
clinical, and ecotoxicological data for a range of substances 
with different modes of action and physico chemical 
properties; evaluation of datasets to pull out major 
relationships
Information from 6 may 
explain different responses of 
humans and ecosystems
M
6 What can be learned about the 
evolutionary conservation of PPCP 
targets across species and life stages 
in the context of potential adverse 
outcomes and effects?
31.1 Increased knowledge about the conservation of drug targets 
across environmental phyla and taxa through increased 
genome coverage; application of an adverse outcome 
pathway approach to understand relationships between 
target interactions and adverse effects on ecosystems
4 H
7 How can effects from long-term 
exposure to low concentrations of 
PPCP mixtures on non target organisms 
be assessed?
30.1 Large-scale ecoepidemiological studies; development of 
effective ecopharmaco vigilance schemes; long-term well-
controlled effects studies
5 H
8 How can ecotoxicity test methods 
that reflect the different modes of 
action of active PPCPs be developed 
and implemented in customized risk 
assessment strategies?
29.8 Development of strategies that integrate information on 
pharmacology, target conservation, and adverse outcome 
pathways to identify the best strategy for assessing the 
ecotoxicological effects of PPCPs
Could be informed by 4, 5, 
and 6.
L if other 
questions 
addressed
9 What are the environmental exposure 
pathways for organisms (including 
humans) to PPCPs in the environment, 
and are any of these overlooked in 
current risk assessment approaches?
25.7 Review of potential pathways of release of PPCPs to the 
environment at different stages of the product lifecycle 
for different regions of the world; analysis of existing risk 
assessment frameworks against this information; refinement 
of frameworks to include ignored exposure pathways where 
appropriate
Could help to inform 2 and 17. L–M
10 How can the efficacy of risk 
management approaches be 
assessed?
23.8 Development of monitoring strategies (regarding use, 
disposal, occurrence, and impacts) at different stages of 
the product life cycle; some socio economic and cost-benefit 
analysis aspects should be included
None M
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was also dominated by North American (51%) 
and European attendees (14.6%) and represen-
tatives of multi national corporations (34%). 
Two sub sequent regional workshops were held 
in South Korea and Australia to determine 
the relevance of the 20 questions to the East 
Asian and Australia/New Zealand regions, 
respectively, and to identify additional ques-
tions that may be important to these regions. 
Participants at these workshops agreed that 
the 20 questions were of high importance to 
the East Asian and Australasian regions, and 
they highlighted the fact that these regions 
had unique charac teristics (e.g., in terms of 
biodiversity) that should be considered when 
addressing the questions. Participants felt that 
important issues, such as better risk commu-
nication, consideration of cultural differences, 
and the impacts of natural medicines had 
also been overlooked. The conclusions of 
these later workshops will be presented in 
detail elsewhere. 
Conclusions
The present study is the first to use the key 
question approach to identify key issues regard-
ing exposure, effects, and risks of PPCPs in the 
Table 1. Continued.
Rank Question
Most important 
question (%)a Potential approaches Related questions (by rank)
Level of 
challenge
11 How can the risks to human health 
that arise from antibiotic resistance 
selection by PPCPs in the natural 
environment be assessed?
23.6 Development of risk assessment strategies; development 
of effective ecopharmaco vigilance for antibiotics to assess 
the development and frequency of antibiotic resistance in 
natural microbial communities and clinical isolates
Information from 3 could be 
helpful in the development of 
risk assessment schemes
H
12 How can the uptake of ionizable 
PPCPs into aquatic and terrestrial 
organisms and through food chains be 
predicted?
22.4 Studies into the uptake, depuration, and metabolism of 
a range of ionizable PPCPs with different properties into 
water-, soil-, and sediment-dwelling organisms with 
different traits; food chain studies with selected substances; 
development of uptake models
May help inform 1 and 15 L–M
13 How can data on the occurrence of 
PPCPs in the environment and quality 
of ecosystems exposed to PPCPs be 
used to determine whether current 
regulatory risk assessment schemes 
are effective?
22.1 Collation of data on the occurrence of PPCPs in receiving 
systems and on associated ecology; analysis of data against 
exposure predictions from environmental risk assessments; 
evaluation of quality of ecosystems receiving PPCPs; when 
impacts cannot be ruled out, it will be necessary to tease 
out the impacts of PPCPs on a system against impacts of 
other stressors.
None M–H
14 If a PPCP has an adverse 
environmental risk profile, what can 
be done to manage and mitigate the 
risks?
19.0 Review of different management and mitigation options for 
different stages of the product life cycle; generation of data on 
the efficacy of a particular option; assessment of economic and 
other implications of an option so that benefits of a system can 
be weighed up against the potential costs
Could be informed by data 
from 1, 3, and 10.
M
15 Do PPCPs pose a risk to wildlife such 
as mammals, birds, reptiles and 
amphibians?
17.1 Development of exposure models for birds, amphibians, 
and mammals; evaluation of toxic effects of PPCPs on birds, 
mammals, and amphibians using either existing preclinical 
data or well designed studies; use of environmental 
monitoring studies
Data from 5, 9, and 12 may 
be useful 
M–H
16 How can the environmental risks 
of metabolites and environmental 
transformation products of PPCPs be 
measured or predicted?
17.1 Development of improved analytical approaches for 
identifying metabolites and transformation products; 
studies to assess relative effects of transformation 
products compared with parent compounds; development of 
assessment schemes for transformation products
Information from 5 may help L–M
17 How can regions where PPCPs pose 
the greatest risk to environmental and 
human health, either now or in the 
future, be identified?
16.2 Evaluation of usage patterns of PPCPs in different 
geographical regions, as well as local practices (e.g., for 
disposal and treatment of contaminated material) and 
potential differences in sensitivity of organisms, both 
for now and in the future; development of new exposure 
assessment models if appropriate; use of information to 
establish potential risks
Data from 9 will be useful L–M
18 What effluent treatment methods 
are effective in reducing the effects 
of PPCPs in the environment while 
not increasing the toxicity of whole 
effluents?
16.2 Targeted laboratory and field studies, which consider local 
conditions and constraints, to determine how PPCPs are 
removed in treatment processes and whether transformation 
products are formed; use of biologically based assessments 
to assess effectiveness of a particular treatment method
Information from 4 and 8 
could assist in the selection of 
biological end points to use; 
data from 16 may help
M
19 Can non animal testing methods be 
developed that will provide equivalent 
or better hazard data compared with 
current in vivo methods?
13.2 Review of current non animal methods; assessment of 
information from selected methods against data from 
current in vivo methods; development of recommendations 
on which non animal methods can provide useful data
Knowledge from 5 may help M
20 What is the bioavailability of non-
extractable residues of PPCPs?
 9.4 Improved analytical characterization of the form of PPCP 
NERs; controlled studies on the bioavailability of NERs of 
a range of PPCPs to soil- and sediment-dwelling organisms 
with different traits over time; manipulation studies to 
assess the impacts of climate change, for example, on the 
availability of NERs; development of guidelines for NER 
assessment in risk assessment
None L
Abbreviations: H, high (likely to require large, complex, multidisciplinary research programs and development of new paradigms); M, medium (likely to require large, multidisciplinary 
programs but many of the required tools exist; L, low (readily addressable through focused research programs). 
aWorkshop attendees were sequentially presented with sets of 4 questions and asked to select the highest (most important) and lowest (least important) question from the each set; all 
20 questions were ranked using this process. Values correspond to the proportion of instances that a question was ranked by the attendees as highest in the set of four questions. 
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environment. We see this exercise as the start 
of a broader program, and in the short term we 
are planning a broader global survey to identify 
which questions are most relevant to different 
stake holders and why (additional questions 
proposed by the “local” workshops will be 
included in this exercise). In addition to this 
survey, additional workshops are planned on 
select topics (e.g., anti biotic resistance), and the 
conclusions of the survey and the workshops 
will be disseminated to policy makers around 
the world. We are optimistic that the results 
of this exercise will be invaluable in informing 
the design, coordination, and implementation 
of future research programs on PPCPs in the 
environment. We hope that these programs 
will help us to better understand the potential 
and relative risks of these substances in the 
natural environ ment and to effectively control 
and manage these risks. 
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